Efficacy and Safety Study of EscharEx to Treat (Debride) Hard to Heal Wounds

Inclusion Criteria * Patients, men or women, are between 18 and 90 years of age. * Patient with venous leg ulcer or diabetic (lower extremity) ulcer or traumatic/post operative wound (determined by medical history and physical examination) * Wound is not healing for at least 4 weeks * The necrotic/slough/fibrin non-viable tissue area is at least 50% of wound area (assessed by clinical evaluation) * Wound surface area is in the range of 5- 200 cm2 in the first stage and 3 - 150cm2 in the second stage. * Patient understands the nature of the procedure, able to adhere to the protocol regimen, and provides written informed consent prior to any study procedure * The Wound is classified as a wound involving full skin thickness but not penetrating to cavities or open joint spaces Exclusion Criteria * Evidence of active osteomyelitis of target organ, * Patients with more than one hard to heal wounds wounds which require debridement and with an area greater than or equal to 2cm2, * Presence of purulent discharge, deep-tissue abscess, cellulitis or tissue damage extending \>2 cm around the wound's edge, gangrene or signs of systemic infection, * Wound size decreased by \> 20% after 1 week of standard-of-care-only period (screening period), * Patients with pre-enrolment wounds which are covered by eschar heavily saturated with iodine or by Silver sulfadiazine (SSD) pseudoeschar (e.g. pseudoeschar as a result of SSD treatment), * Ankle-Brachial Index (ABI) ≤ 0.7 or a significant decrease in the blood flow of the extremity as demonstrated by US doppler. * Wound has sinus tracts or tunnels extending under healthy tissue, * Patients undergoing renal or peritoneal dialysis, * Recent history (less than 4 weeks) of myocardial infarction (MI) or concurrent acute injury or disease that might compromise the patient's welfare, * Any condition that would preclude safe participation in the study: evidence of significant hematological (severe pre-existing coagulation disorder), cardiovascular, liver or neoplastic disease, or any other immediate life threatening condition, * Patient is currently receiving, or has received at any time within one month prior to enrollment, any medications or treatments known to affect the wound healing processes; these include: chronic systemic steroid intake with topical skin changes (thin, fragile with multiple hematomas and previous laceration history, immuno-suppressive drugs, radiation therapy and chemotherapy. * History of allergy or atopic disease or a known sensitivity to pineapples, papaya, bromelain or papain, * Pregnant women (positive pregnancy test) or nursing mothers, * Participation in another investigational drug trial within 30 days prior to enrollment or anticipated participation while enrolled in the study, * Concurrent use of non-approved drugs or alcohol abuse. * Patients with poor nutritional status (albumin \< 2.5g/dl), poor diabetic control (HbA1c \> 12%), anemia (hemoglobin\<8 g/dL), a leukocyte counts \< 4,000// μl or \>15000/μl, abnormal liver function (AST, ALT\>2 x upper limit of normal range), renal failure (Cr \> 3 mg/dl); * Mentally incapacitated adults who are incapable of giving legal consent (e.g. dementia, psychiatric patients, etc), * Patients with general skin disorders (Psoriasis, Panniculitis, ect) that might deteriorate as a result of local trauma. * Patients with skin disorders unrelated to the wound that are presented adjacent to the wound * Clinical suspicion of skin cancer associated with the wound (e.g, BCC, SCC), which was not ruled out by biopsy Patients with diagnosed Sepsis during screening phase, * Patients suffering from Idiopathic Pruritus.